MCA
REGN icon

Magnolia Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Magnolia Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-368
Closed -$223K – 209
2021
Q3 		$223K Buy
+368
New +$228K 0.08% 168

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Magnolia Capital Advisors's REGN Position: Q4 2021 in Review

Magnolia Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2021, closing a stake of 368 shares — an estimated $223K sold.

Magnolia Capital Advisors first reported a position in REGN in Q3 2021 and held it in 1 quarter. The position peaked at $223K in Q3 2021. 1,078 funds tracked by Wall St. Rank hold REGN as of Q4 2021.

  • Magnolia Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Magnolia Capital Advisors sold 368 Regeneron Pharmaceuticals shares in Q4 2021, an estimated $223K.
  • Magnolia Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Magnolia Capital Advisors's Regeneron Pharmaceuticals position peaked at $223K in Q3 2021.
  • 1,078 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2021.

Based on Magnolia Capital Advisors's 13F filing for Q4 2021, filed 26 Jan 2022.